Adrian Mercado-Alamo
Interventional Cardiology · Las Vegas, NVNPI 1275948333
Payments from drug & device makers
Across 472 payments — averaging $250.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$63K
- Shockwave Medical, Inc$16K
- Abbott$15K
- Stryker$12K
- Abiomed$3K
- Amgen$1K
- plus $8K from 33 others
What the payments were for
- Consulting fees$20,00017%
- Speaking & faculty fees$70,85060%
- Travel & lodging$8,9888%
- Food & beverage$17,11315%
- Education$9691%
- Gifts$840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inari Medical, Inc. | 55 | $63,109 |
| Shockwave Medical, Inc | 15 | $15,790 |
| Abbott | 73 | $15,418 |
| Stryker | 11 | $11,905 |
| Abiomed | 44 | $2,934 |
| Amgen | 33 | $1,022 |
| W. L. Gore & Associates, Inc. | 8 | $987 |
| Cardiva Medical, Inc. | 41 | $760 |
| Novartis | 30 | $612 |
| Boston Scientific | 14 | $595 |
| Cardiovascular Systems Inc. | 7 | $589 |
| Penumbra, Inc. | 6 | $524 |
| Johnson & Johnson | 13 | $358 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 19 | $358 |
| Cathworks, Inc. | 3 | $318 |
| Merck | 14 | $317 |
| E.r. Squibb & Sons, L.L.C. | 14 | $290 |
| AstraZeneca | 10 | $249 |
| Medtronic | 5 | $240 |
| Pfizer | 13 | $238 |
| Viz.ai, Inc. | 2 | $233 |
| Cardinal Health 200 LLC | 7 | $220 |
| Cvrx, Inc. | 3 | $142 |
| Chiesi USA, Inc. | 4 | $130 |
| Esperion Therapeutics, Inc. | 1 | $115 |
| Boehringer Ingelheim | 5 | $109 |
| Alnylam Pharmaceuticals Inc. | 4 | $96 |
| Philips North America LLC | 4 | $62 |
| Bard Peripheral Vascular, Inc. | 2 | $42 |
| Scpharmaceuticals Inc. | 1 | $34 |
| Actelion Pharmaceuticals US, Inc. | 1 | $32 |
| Angiodynamics, Inc. | 2 | $31 |
| EKOS Corporation | 2 | $27 |
| Lexicon Pharmaceuticals, Inc. | 1 | $23 |
| Cordis US CORP. | 1 | $23 |
| Teleflex LLC | 1 | $20 |
| Lantheus Medical Imaging, Inc. | 1 | $18 |
| Smith+Nephew | 1 | $18 |
| Reflow Medical Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$73,891
- CT THROMBECTOMY SYSTEM KIT$73,891
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$15,771
- DRAGONFLY OPSTAR$6,533
- COROFLOW$6,014
- Impella$2,217
- GORE CARDIOFORM Septal Occluder$791
- Repatha$785
- CLOTTRIEVER BOLD CATHETER$414
- Optis Coronary Imaging System$354
- CARDIOMEMS$315
- FFRangio$293
- OPTIS$293
- Xience Sierra Coronary Stent$288
- Indigo System$272
- Diamondback Coronary$270
- Coronary Orbital Atherectomy System$264
- Dragonfly OCT$147
- Viz.AI LVO$147
- XIENCE SIERRA$143
How this compares
$118,004 in reported general payments places this provider in the 95th percentile of 62 interventional cardiology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 158 | $142,438 |
| EntrestoSacubitril/Valsartan | 56 | $47,290 |
| XareltoRivaroxaban | 37 | $26,258 |
| FarxigaDapagliflozin Propanediol | 32 | $21,076 |
| Repatha SureclickEvolocumab | 31 | $20,527 |
| BrilintaTicagrelor | 24 | $17,385 |
| Ranolazine ErRanolazine | 16 | $1,853 |
| Metoprolol Succinate | 120 | $1,326 |
| ClopidogrelClopidogrel Bisulfate | 146 | $984 |
| Losartan Potassium | 85 | $594 |
| Atorvastatin Calcium | 127 | $582 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 12 | $431 |
| Lisinopril | 34 | $330 |
| Nifedipine ErNifedipine | 11 | $322 |
| Rosuvastatin Calcium | 37 | $319 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $238 | $142,438158 claims |
| NovartisEntresto | $612 | $47,29056 claims |
| AstraZenecaFarxiga, Brilinta | $249 | $38,46056 claims |
| Johnson & JohnsonXarelto | $358 | $26,25837 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 62 interventional cardiology providers in Nevada.
Other interventional cardiology in Las Vegas
- Cres MirandaLas Vegas$660K
- Nayab ZafarLas Vegas$102K
- William ChuLas Vegas$75K
- Neville MistryLas Vegas$40K
- Leon VarjabedianLas Vegas$34K
- Moniz DawoodLas Vegas$29K
- Andrew LuxhojLas Vegas$22K
- Mohi AlkadriLas Vegas$20K
- John BedottoLas Vegas$20K
- James LallyLas Vegas$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.